All Pharmaceutical Microbiology articles – Page 3
-
NewsRepurposed antibiotic shows promise against Central Nervous System Tuberculosis
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study. Published in the Journal of Neuroinflammation, the ...
-
NewsNew drug target identified in fight against resistant infections
Researchers have identified new drug targets within a special repair system possessed by certain bacteria, known as Rtc, which enables them to counteract the effects of these antibiotics.
-
NewsLow-dose cannabis compound reduces side effects of HIV treatment
Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART). Benefits included increased production of serotonin, while inflammation, cholesterol and harmful secondary bile acids were all reduced.
-
NewsBiochemists search for cellular vulnerabilities in killer ‘superbugs’
Helen Zgurskaya and Valentin Rybenkov are leading a five-year, $5.3 million project funded by the National Institute of Allergy and Infectious Diseases to find new ways to deliver lifesaving drugs directly into resistant pathogens.
-
NewsTemporary benefit for immune system in early HIV treatment, but dysregulation returns
A study investigated whether immune dysregulation can be prevented by starting HIV medication immediately after infection. Six months after this early treatment, the immune system did indeed work as in people without HIV, but in the longer term, the immune system was disrupted again.
-
NewsScientists uncover tuberculosis bacterium’s ’heartbeat’, opening door to new treatments
Scientists have identified a molecular system inside Mycobacterium tuberculosis that functions like the organism’s heart or lungs, keeping it alive. The system, known as PrrAB, helps the bacterium generate energy and breathe. When researchers used a gene-silencing tool, the bacterium died.
-
NewsEarly-stage clinical trial demonstrates promise of intranasal influenza vaccine in generating broad immunity
Researchers report encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 ’bird flu’, highlighting the potential of mucosal immunization strategies.
-
NewsAI can speed antibody design to thwart novel viruses: study
Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study
-
NewsNew study finds targets for a new tuberculosis vaccine
A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.
-
NewsBreathing new life Into TB treatment with inhalable nanomedicine
Scientists are developing an inhalable nanosystem to transport TB medicines directly into the lungs, the very place where the bacterium that causes TB hides and thrives. The nanocarrier can hold all four standard TB drugs in a single formulation and release them precisely at the infection site.
-
NewsHorizon Awards 2025: Dr Manu De Rycker named as winner of WH Pierce Prize
Dr Manu De Rycker, a Principal Investigator at the University of Dundee, has been named as the newest winner of the WH Pierce Global Impact in Microbiology Prize.
-
NewsNew compound cuts off protein supply to parasites
There is an urgent need for new active ingredients that are capable of circumventing existing resistances in malaria. Researchers have now identified a new drug candidate, ’Substance 31’, which could enable the development of a new malaria drug.
-
NewsBay Area Lyme Foundation opens applications for 2026 Emerging Leader Awards and research grants
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, has announced its call for applicants from academia and the private sector for the 2026 Emerging Leader Awards (ELA).
-
NewsBacteria deliver synthetic, animal-free way to grow organoids in 3D
Researchers have developed a completely animal-free gel to grow organoids, miniature three dimensional versions of organs. By combining the bacterial protein invasin with a synthetic gel, they created an environment in which organoids can grow and expand long-term.
-
NewsNew hope for cats with eye infections: Study finds common cold sore cream safe and effective for feline use
A common human cold sore cream may soon help cats with painful eye infections: researchers found that 1% penciclovir cream (Fenlips®), when applied to cats’ eyes, was safe, well-tolerated, and maintained antiviral levels for over eight hours.
-
NewsHuman Organ Chip technology sets stage for pan-influenza A CRISPR RNA therapies
Human lung alveolus chip infection model enables investigation of viral replication, inflammatory responses, and genetic off-target effects of a novel pan-influenza CRISPR therapy.
-
NewsIUCN members choose science and ethics in landmark vote on synthetic biology
The Wildlife Conservation Society (WCS) has hailed the adoption of Motion 87, supporting the responsible, evidence-based use of synthetic biology, at the IUCN World Conservation Congress in Abu Dhabi as a historic milestone for global conservation policy.
-
NewsBreakthrough in coronavirus fight: scientists develop powerful bispecific inhibitor to combat a wide range of coronaviruses
Researchers have discovered a powerful bispecific inhibitor capable of combating all existing human-pathogenic coronaviruses, including those resistant to existing treatments like Paxlovid.
-
NewsResearchers discover method to combat antibiotic treatment failure
Researchers explored ways to alter our own immune cells to help antibiotics work more effectively. They identified a small molecule that alters the body’s immune cells, forcing them to ’wake up’ dormant bacteria and make them more vulnerable to antibiotic treatment.
-
NewsCompound from Antarctic microorganism can be used to produce food, cosmetics, and medicine
A bioactive compound produced by the microorganism Bacillus licheniformis, found on Deception Island in Antarctica, has properties that qualify it for use in producing food, cosmetics, pharmaceuticals, and biodegradable materials.